Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-862.21%
operating margin TTM
-656.95%
revenue TTM
9.04 Million
revenue per share TTM
0.08$
valuation ratios | |
|---|---|
| pe ratio | -10.01 |
| peg ratio | 0.43 |
| price to book ratio | -14.44 |
| price to sales ratio | 85.57 |
| enterprise value multiple | -10.29 |
| price fair value | -14.44 |
profitability ratios | |
|---|---|
| gross profit margin | -127.53% |
| operating profit margin | -656.95% |
| pretax profit margin | -862.21% |
| net profit margin | -862.21% |
| return on assets | -52.34% |
| return on equity | 232.87% |
| return on capital employed | -44.26% |
liquidity ratios | |
|---|---|
| current ratio | 6.88 |
| quick ratio | 6.88 |
| cash ratio | 1.59 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 7.57 |
| days of payables outstanding | 40.62 |
| cash conversion cycle | -33.05 |
| receivables turnover | 48.24 |
| payables turnover | 8.99 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.72 |
| debt equity ratio | -1.99 |
| long term debt to capitalization | 2.09 |
| total debt to capitalization | 2.01 |
| interest coverage | -5.96 |
| cash flow to debt ratio | -0.42 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.78 |
| cash per share | 8.02 |
| operating cash flow per share | -3.61 |
| free cash flow operating cash flow ratio | 1.05 |
| cash flow coverage ratios | -0.42 |
| short term coverage ratios | -11.41 |
| capital expenditure coverage ratio | -21.17 |
Frequently Asked Questions
When was the last time Cytokinetics, Incorporated (NASDAQ:CYTK) reported earnings?
Cytokinetics, Incorporated (CYTK) published its most recent earnings results on 05-11-2025.
What is Cytokinetics, Incorporated's current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Cytokinetics, Incorporated (NASDAQ:CYTK)'s trailing twelve months ROE is 232.87%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Cytokinetics, Incorporated (CYTK) currently has a ROA of -52.34%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CYTK's net profit margin stand at?
CYTK reported a profit margin of -862.21% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CYTK's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.88 in the most recent quarter. The quick ratio stood at 6.88, with a Debt/Eq ratio of -1.99.